Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 117-126

  Tahir, Salahaldin A ^a   Kurosaka, Shinji ^b   Tanimoto, Ryuta ^c   Goltsov, Alexei A ^a   Park, Sanghee ^a   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KITASATO UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Biomarkers; Caveolin 1; Prostate cancer; Tyrosine kinase inhibitor

Indexed keywords

CAVEOLIN 1; DASATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

BIOMARKERS; CAVEOLIN-1; PROSTATE CANCER; TYROSINE KINASE INHIBITOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CAVEOLIN 1; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873472216     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22633     Document Type: Article

References (47)

1. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275:L843-51; PMID:9815100.
2. Sternberg PW, Schmid SL. Caveolin, cholesterol and Ras signalling. Nat Cell Biol 1999; 1:E35-7; PMID:10559891; http://dx.doi.org/10.1038/10028.
3. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008; 84:177-89; PMID:18300018; http://dx.doi.org/10. 1080/09553000701745293.
4. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288:C494-506; PMID:15692148; http://dx.doi.org/10.1152/ajpcell.00458.2004.
5. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 2010; 13:6-11; PMID:19581923; http://dx.doi.org/10.1038/pcan.2009. 29.
6. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005; 280:25134-45; PMID:15802273; http://dx.doi.org/10.1074/jbc.M501186200.
7. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, et al. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 2009; 7:1446-55; PMID:19737975; http://dx.doi.org/ 10.1158/1541-7786.MCR-09-0071.
8. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al.; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596-605; PMID:17404365; http://dx.doi.org/10.1200/JCO.2006.10. 1949.
9. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20; PMID:15470214; http://dx.doi.org/10.1056/NEJMoa041318.
10. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009; 7:1781-91; PMID:19903767; http://dx.doi.org/10.1158/1541-7786.MCR-09-0255.
11. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61:4386-92; PMID:11389065.
12. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23:9389-404; PMID:14645548; http://dx.doi.org/10. 1128/MCB.23.24.9389-9404.2003.
13. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 2009; 8:2286-96; PMID:19923922.
14. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgeninsensitive prostate cancer. Cancer Res 2001; 61:3882-5; PMID:11358800.
15. Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer 2008; 122:520-5; PMID:17943731; http://dx.doi.org/10.1002/ijc.23142.
16. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62:2423-9; PMID:11956106.
17. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68:731-9; PMID:18245473; http://dx.doi.org/10.1158/0008-5472. CAN-07-2668.
18. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-61; PMID:15615512; http://dx.doi.org/10.1021/jm049486a.
19. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65:9185-9; PMID:16230377; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-1731.
20. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-8; PMID:12748309.
21. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465-76; PMID:14654525.
22. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-605; PMID:12531805; http://dx.doi.org/10.1182/ blood-2002-07-2307.
23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37; PMID:12538485.
24. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734-45; PMID:17690708; http://dx.doi.org/10.1038/nrd2380.
25. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9:3653-9; PMID:14506154.
26. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68:3323-33; PMID:18451159; http://dx.doi.org/10.1158/0008-5472.CAN-07-2997.
27. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27:6365-75; PMID:18679417; http://dx.doi.org/10.1038/onc.2008. 250.
28. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12:4872-5; PMID:16914574; http://dx.doi.org/10.1158/1078-0432.CCR-06-0417.
29. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9:66-76; PMID:19149483.
30. Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010; 6:1175-93; PMID:20684746; http://dx.doi.org/10.1517/1742525 5.2010.506873.
31. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011; 38(Suppl 1):S10-9; PMID:21419931; http://dx.doi.org/10.1053/j.seminoncol. 2011.01.018.
32. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010; 11:992-1000; PMID:20667780; http://dx.doi.org/10.1016/S1470-2045(10)70088-7.
33. Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets 2009; 9:738-47; PMID:19754358; http://dx.doi.org/10.2174/156800909789271530.
34. Abouantoun TJ, Castellino RC, MacDonald TJ. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 2011; 101:215-26; PMID:20524040; http://dx.doi.org/10.1007/s11060- 010-0259-9.
35. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67:2226-38; PMID:17332353; http://dx.doi.org/10.1158/0008-5472.CAN-06-3633.
36. Aoki T, Nomura R, Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 1999; 253:629-36; PMID:10585286; http://dx.doi.org/10.1006/excr.1999.4652.
37. Zundel W, Swiersz LM, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol 2000; 20:1507-14; PMID:10669728; http://dx.doi.org/10. 1128/MCB.20.5.1507-1514.2000.
38. Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, et al. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer 2009; 125:1514-22; PMID:19521982; http://dx.doi.org/10.1002/ijc.24451.
39. Zhang B, Peng F, Wu D, Ingram AJ, Gao B, Krepinsky JC. Caveolin-1 phosphorylation is required for stretchinduced EGFR and Akt activation in mesangial cells. Cell Signal 2007; 19:1690-700; PMID:17446044; http://dx.doi.org/10.1016/j.cellsig.2007.03.005.
40. Percy CJ, Pat BK, Healy H, Johnson DW, Gobe GC. Phosphorylation of caveolin-1 is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells. Pathology 2008; 40:694-701; PMID:18985523; http://dx.doi.org/10.1080/00313020802436402.
41. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68:8210-20; PMID:18922892; http://dx.doi.org/10.1158/0008-5472.CAN-08-0343.
42. Schlegel A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem 2001; 276:4398-408; PMID:11078729; http://dx.doi.org/10. 1074/jbc. M005448200.
43. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; 284:34211-22; PMID:19801663; http://dx.doi.org/10.1074/jbc.M109. 041152.
44. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69:5601-9; PMID:19549916; http://dx.doi.org/10.1158/0008-5472.CAN-08-3860.
45. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci 2004; 117:5343-51; PMID:15466889; http://dx.doi.org/10.1242/jcs.01420.
46. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al.; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59; PMID:18309951; http://dx.doi.org/10.1200/JCO.2007.12.4487.
47. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007; 8:R255; PMID:18047674; http://dx.doi.org/10.1186/gb-2007-8-11-r255.